Lilly lifts 2020 guidance, sets 2021 outlook ahead of consensus

 

• Eli Lilly (NYSE:LLY) sees full-year 2020 non-GAAP EPS of $7.45 - $7.65, up from previous guidance of $7.20 - $7.40, and well ahead of consensus $7.24.
• 2020 Revenue is now expected to be $24.2B to $24.7B from the previous $23.7B-$24.2B, and consensus of $23.95B.
• Non-GAAP gross margin is trimmed roughly 100 basis points to about 79%.
• Full-year 2021 non-GAAP EPS is seen at $7.75 - $8.40 vs. estimates for $8.08.
• Full-year 2021 revenue is expected at $26.5B - $28.0B vs. consensus $26.5B. The revenue estimate includes $1B-$2B from Covid-therapies.
• https://seekingalpha.com/news/3644332-lilly-lifts-2020-guidance-sets-2021-outlook-ahead-of-consensus-shares-rise-premarket